Technical Analysis for INZY - Inozyme Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.74 | -1.79% | -0.05 |
INZY closed down 0.71 percent on Wednesday, November 20, 2024, on 1.44 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -1.79% | |
| Doji - Bullish? | Reversal | -1.79% | |
| Lower Bollinger Band Walk | Weakness | -1.79% | |
| New 52 Week Low | Weakness | -1.79% | |
| Wide Bands | Range Expansion | -1.79% | |
| Down 3 Days in a Row | Weakness | -1.79% | |
| Down 4 Days in a Row | Weakness | -1.79% | |
| Down 5 Days in a Row | Weakness | -1.79% | |
| Oversold Stochastic | Weakness | -1.79% | |
| New 52 Week Closing Low | Bearish | -2.49% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 1 hour ago |
| Down 5% | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| New 52 Week Low | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.795 |
| 52 Week Low | 2.69 |
| Average Volume | 272,814 |
| 200-Day Moving Average | 5.11 |
| 50-Day Moving Average | 4.79 |
| 20-Day Moving Average | 3.97 |
| 10-Day Moving Average | 3.45 |
| Average True Range | 0.27 |
| RSI (14) | 16.67 |
| ADX | 35.93 |
| +DI | 8.96 |
| -DI | 44.60 |
| Chandelier Exit (Long, 3 ATRs) | 4.46 |
| Chandelier Exit (Short, 3 ATRs) | 3.51 |
| Upper Bollinger Bands | 5.29 |
| Lower Bollinger Band | 2.66 |
| Percent B (%b) | 0.05 |
| BandWidth | 66.26 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.42 |
| MACD Histogram | -0.1246 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.07 | ||||
| Resistance 3 (R3) | 3.07 | 2.97 | 3.03 | ||
| Resistance 2 (R2) | 2.97 | 2.90 | 2.98 | 3.01 | |
| Resistance 1 (R1) | 2.88 | 2.86 | 2.88 | 2.88 | 2.99 |
| Pivot Point | 2.79 | 2.79 | 2.79 | 2.79 | 2.79 |
| Support 1 (S1) | 2.69 | 2.71 | 2.70 | 2.70 | 2.59 |
| Support 2 (S2) | 2.60 | 2.67 | 2.60 | 2.57 | |
| Support 3 (S3) | 2.51 | 2.60 | 2.56 | ||
| Support 4 (S4) | 2.51 |
